Intangible Assets, net (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible asset

The gross carrying amounts and net book value of our intangible assets are as follows:

		June 30, 2023
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value
Barhemsys intangible (1)	9	$	70,319	$	(8,448)	$	61,871
Byfavo intangible (1)	9	33,714		(3,783)		29,931
Ryanodex intangible (2)	9	15,000		(8,794)		6,206
PEMFEXY intangible (3)	2	15,000		(5,602)		9,398
Vasopressin milestone (4)	1	750		(750)		—
Total		$	134,783	$	(27,377)	$	107,406

		December 31, 2022
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value
Barhemsys intangible (1)	9	$	70,319	$	(4,462)	$	65,857
Byfavo intangible (1)	9	33,714		(1,989)		31,725
Ryanodex intangible (2)	9	15,000		(7,402)		7,598
PEMFEXY intangible (3)	2	15,000		(1,888)		13,112
Vasopressin milestone (4)	1	750		(715)		35
Total		$	134,783	$	(16,456)	$	118,327

(1) Represents intangible assets acquired in the Acacia acquisition as detailed in Note 13.

(2) Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.

(3) Represents a one-time payment made to reduce the royalties payable to a third party on PEMFEXY net sales.

(4) Represents milestone paid to a third party upon FDA approval of vasopressin.

Schedule of future amortization expense of finite-lived intangible assets

Based on definite-lived intangible assets recorded as of June 30, 2023, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:

	Estimated Amortization Expense
Year Ending December 31,
2023 (remainder)	11,034
2024	19,780
2025	13,917
2026	11,615
2027	11,615
Thereafter	39,445
Total estimated amortization expense	$	107,406